Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Culture
Culture Ministry honors late influential Taiwanese painter
04/20/2025 08:30 PM - Culture
Indonesian diaspora celebrates Kartini Day in Taipei
04/20/2025 06:35 PM - Culture
Nymphia Wind crowns new RuPaul's Drag Race queen in glorious return
04/20/2025 05:04 PM - Business
TSMC forecasts healthy growth amid foundry sector recovery
04/20/2025 05:00 PM - Politics
Ex-NTU head warns Taiwan faces risks from both China and the U.S.
04/20/2025 04:30 PM